Zim Laboratories Limited — Investor Meet, 23-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Zim Laboratories reported Q4 FY26 operating income of INR 105.3 Cr and PAT of INR 3.7 Cr, with full-year operating income at INR 374.4 Cr. The company has completed EU GMP remediation and underwent a positive re-inspection by German and Portuguese authorities, with formal results expected soon. Management is confident in regulatory reinstatement within two months. They target stronger FY27 performance, driven by a growing NIP/OTF pipeline (17 products commercializing in 24 months) and expansion into other markets. Mid-to-upper teens EBITDA margins are anticipated. The company expressed confidence in future growth and operational execution.